Drug Information

Drug General Information
Drug ID
D00IZD
Former ID
DIB014323
Drug Name
DVC1-0101
Synonyms
Ischemia gene therapy, DNAVEC\Kyushu University; FGF2-carrying Sendai virus, DNAVEC\Kyushu University; SeV-FGF2 gene therapy (virus recombinant, ischaemia) DNAVEC\Kyushu University
Indication Arteriosclerosis [ICD9: 440; ICD10:I70] Phase 2 [532195]
Company
DNAVEC Corp
Target and Pathway
Target(s) Heparin-binding growth factor 2 Target Info Modulator [532195]
KEGG Pathway MAPK signaling pathway
Ras signaling pathway
Rap1 signaling pathway
PI3K-Akt signaling pathway
Signaling pathways regulating pluripotency of stem cells
Regulation of actin cytoskeleton
Pathways in cancer
Proteoglycans in cancer
Melanoma
NetPath Pathway IL1 Signaling Pathway
Pathway Interaction Database Glypican 1 network
Angiopoietin receptor Tie2-mediated signaling
Integrins in angiogenesis
Syndecan-4-mediated signaling events
FGF signaling pathway
Reactome PI3K Cascade
PIP3 activates AKT signaling
FGFR4 ligand binding and activation
FGFR3c ligand binding and activation
FGFR2c ligand binding and activation
FGFR2b ligand binding and activation
FGFR3 mutant receptor activation
Activated point mutants of FGFR2
Constitutive Signaling by Aberrant PI3K in Cancer
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
Syndecan interactions
Non-integrin membrane-ECM interactions
Phospholipase C-mediated cascade: FGFR1
Phospholipase C-mediated cascade
Phospholipase C-mediated cascade
Phospholipase C-mediated cascade
SHC-mediated cascade:FGFR1
PI-3K cascade:FGFR1
FRS-mediated FGFR1 signaling
PI-3K cascade:FGFR2
SHC-mediated cascade:FGFR2
FRS-mediated FGFR2 signaling
SHC-mediated cascade:FGFR3
FRS-mediated FGFR3 signaling
PI-3K cascade:FGFR3
FRS-mediated FGFR4 signaling
SHC-mediated cascade:FGFR4
PI-3K cascade:FGFR4
Negative regulation of FGFR1 signaling
Negative regulation of FGFR2 signaling
Negative regulation of FGFR3 signaling
Negative regulation of FGFR4 signaling
RAF/MAP kinase cascade
WikiPathways Regulation of Actin Cytoskeleton
Endochondral Ossification
Differentiation Pathway
Cardiac Hypertrophic Response
Syndecan interactions
Extracellular matrix organization
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
PIP3 activates AKT signaling
Cardiac Progenitor Differentiation
Integrated Pancreatic Cancer Pathway
Neural Crest Differentiation
miR-targeted genes in squamous cell - TarBase
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
Signaling by FGFR
MicroRNAs in cardiomyocyte hypertrophy
Angiogenesis
References
Ref 532195DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
Ref 532195DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.